Actelion's clazosentan misses Phase III endpoint

Actelion Ltd. (SIX:ATLN) said clazosentan missed the primary endpoint in the Phase III CONSCIOUS-2 trial to prevent cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). The endothelin A receptor antagonist did not significantly reduce cerebral vasospasm-related morbidity and all-cause mortality from baseline vs. placebo within six weeks post-aSAH. The double-blind, international trial enrolled more than 1,150 patients.

Actelion said it is evaluating the data and will discuss how best to proceed with the ongoing Phase III CONSCIOUS-3 trial of clazosentan in post-aSAH patients who underwent coiling to secure their aneurysm with that study's steering committee. The company also said it will provide an update on the clazosentan development program in its 3Q10 earnings report on Oct. 21. Actelion was down CHF3.46 to CHF40 on Monday. ...